Proactive: Racura Oncology activates Hong Kong trial site

Racura Oncology CEO Dr Daniel Tillett spoke with Proactive about the activation of the company’s first clinical site in Hong Kong for its Phase 1 RC220 trial in advanced solid tumours. Located at Queen Mary Hospital, this marks the start of patient enrolment in the region, with screening underway and the first patient expected to begin treatment this month.

Watch the interview here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@racuraoncology.com T: +61 2 8051 3043
© 2026 Racura Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Racura Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.